Gensight Biologics SA SIGHT.PA
€0.08 €0.00 (0.50%) 1D
Last Updated: Jun 23, 12:00 AM·XPAR
Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
SIGHT.PA Shariah Compliance
Screening Methodology: AAOIFI
HALAL
Last Updated: July 28, 2025
Report Source: 2024 Annual Report
Gensight Biologics SA. Stock Analysis SIGHT.PA
France Health Care Nano Cap Report: GenSight Biologics SA is a clinical-stage gene therapy company, which engages in research and development of novel therapies for mitochondrial and neurodegenerative diseases of the eye. The company employs 13 full-time employees The company went IPO on 2016-07-13. The firm develops and commercializes gene therapy-based treatments of retinal degenerative diseases. The company develops approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from low vision or blindness. The firm intends notably to develop a gene replacement therapy for Leber's hereditary optic neuropathy (LHON) and an optogenetic therapy for retinitis pigmentosa (RP).
Read More Gensight Biologics SA (SIGHT.PA) Chart
Key Statistics of Gensight Biologics SA (SIGHT.PA)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
€0.08Volume
660.74KP/E Ratio (TTM)
-52 Week Range
Market Cap
20.56MAvg. Volume
110.46KDividend Yield
-Financial Metrics & Statements of Gensight Biologics SA (SIGHT.PA)
FAQ's for Gensight Biologics SA (SIGHT.PA)
- According to Musaffa’s Shariah screening methodology, Gensight Biologics SA (SIGHT.PA) is currently classified as HALAL as of July 2025. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Gensight Biologics SA using these criteria to determine its compliance status.
- Muslim investors may consider investing in Gensight Biologics SA if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Gensight Biologics SA by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Gensight Biologics SA may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Gensight Biologics SA on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.